

Applicants: David M. Stern et al.
Serial No.: 09/638,648
Filed: August 14, 2000
Page 2

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously Presented) A method for decreasing cerebral vasoconstriction in a subject suffering from an Alzheimer's disease-type pathology, which comprises administering to the subject an inhibitor of receptor for advanced glycation endproduct (RAGE) in an effective amount to inhibit transcytosis of amyloid- β peptides across the blood-brain barrier in the subject, thereby decreasing cerebral vasoconstriction in the subject.
2. (Previously Presented) The method of claim 1, wherein the subject is a human subject.
3. (Canceled)
4. (Previously Presented) The method of claim 1, wherein the subject suffers from Alzheimer's disease.
5. (Canceled)
6. (Canceled)
7. (Previously Presented) The method of claim 1, wherein the inhibitor is a molecule having a molecular weight from about

Applicants: David M. Stern et al.

Serial No.: 09/638,648

Filed: August 14, 2000

Page 3

500 daltons to about 100 kilodaltons.

8. (Previously Presented) The method of claim 1, wherein the inhibitor is an organic molecule or an inorganic molecule.
9. (Previously Presented) The method of claim 1, wherein the inhibitor is a polypeptide or a nucleic acid molecule.
10. (Previously Presented) The method of claim 1, wherein the inhibitor is soluble receptor for advanced glycation endproduct.
11. (Previously Presented) The method of claim 1, wherein the inhibitor is an antibody which specifically binds to receptor for advanced glycation endproduct.
- 12-15. (Canceled)
16. (Previously Presented) A method for treating Alzheimer's disease in a subject which comprises administering to the subject an effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) activity so as to increase cerebral blood flow in the subject and thereby treat Alzheimer's disease in the subject.